All News

Investigators: Biosimilar Pegfilgrastim Has Advantages Over Wearable Injector

December 1, 2020

Tony Hagen

Article

The wearable injector has a failure rate that adds hospitalization costs; therefore, biosimilar pegfilgrastim may hold cost advantages, investigators conclude.

Celltrion Relies on Domestic Construction Amid the Pandemic

December 1, 2020

Tony Hagen

Article

The Songdo district of Incheon, Republic of Korea, is rapidly becoming a major biopharmaceuticals production center.

Biosimilar Legal Roundup: November 2020

November 30, 2020

Skylar Jeremias

Article

In November, the Supreme Court heard arguments on the Affordable Care Act, Europe fired up its efforts to create a more biosimilar-friendly environment, and Genentech fought to protect its bevacizumab franchise.

Poll: How Much Do You Know About Biosimilar Suffixes?

November 30, 2020

Article

Biosimilar suffixes were intended to help with pharmacovigilance, but they are not widely understood.

Henlius, Celltrion Group Report Product Development Advances

November 28, 2020

Tony Hagen

Article

A Shanghai Henlius Biotech study demonstrates equivalence for its bevacizumab candidate, and Celltrion moves forward with a trial for a SARS-CoV-2 candidate.

EC Eyes Enhancements for a Post–COVID-19 Marketplace

November 27, 2020

Tony Hagen

Article

The European Commission (EC) said it will take the lessons learned from the coronavirus disease 2019 (COVID-19) pandemic and build a better marketplace for generics and biosimilars.

Samsung Bioepis CEO Discusses the Pandemic's Effect on Biosimilars

November 26, 2020

Tony Hagen

Article

Christopher Hansung Ko, PhD, president and CEO of biosimilars company Samsung Bioepis, discusses innovations and precautions the pandemic has brought to the field of biosimilars.

Alvotech Scientific Officer Describes Company's Global Biosimilars Strategy

November 25, 2020

Tony Hagen

Article

Joseph E. McClellan, PhD, MBA, discussed navigation of regulatory hurdles as the company continues its quest to line up distribution partnership deals across the globe.

Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars

November 24, 2020

Skylar Jeremias

Article

Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.

Investigators Look to Cut Breast Cancer Recurrence With Posttrastuzumab Therapy

November 24, 2020

Tony Hagen

Article

GP2 peptide/G-CSF in HER2-equivocal and -positive breast cancer has shown promise.

x